Hypothyroidism

The FDA ( U.S. Food and Drug Administration ) has approved Opdivo ( Nivolumab ) 240 mg injection for intravenous...


Castration-resistant prostate cancer ( CRPC ) is defined as disease progression during ADT ( androgen deprivation therapy ), with serum...


The European Commission ( EC ) has approved Opdivo ( Nivolumab ) plus Yervoy ( Ipilimumab ) with two cycles...


Opdivo ( Nivolumab ) 1 mg/kg plus Yervoy ( Ipilimumab ) 3 mg/kg ( injections for intravenous use ) was...


KEYNOTE-427, a single-arm, open-label, phase 2 study, has shown antitumor activity with first-line Pembrolizumab ( Keytruda ) monotherapy in non-clear...


SPARTAN has evaluated Apalutamide ( Erleada ) versus placebo in patients with nonmetastatic castration-resistant prostate cancer ( nmCRPC ) and...


Apalutamide in combination with ADT prolonged median overall survival by 14 months and decreased the risk of death by 22%. Median...


The treatment of relapsed or refractory diffuse large B-cell lymphoma ( R/R DLBCL ) remains challenging. Atezolizumab ( Tecentriq )...


The FDA ( U.S. Food and Drug Administration ) has announced Project Orbis, an initiative of the FDA Oncology Center...


The European Commission ( EC ) has approved Bavencio ( Avelumab ) in combination with Axitinib ( Inlyta ) for...


The FDA ( Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination with...


The US Food and Drug Administration ( FDA ) has approved Bavencio ( Avelumab ) in combination with Inlyta (...


Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy have...


Updated preliminary clinical data from an ongoing phase I dose escalation and expansion study evaluating the safety and efficacy of...


The results from an interim analysis of KEYNOTE-057, a phase 2 trial evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy,...


Activation of the PD-1 pathway has been implicated in resistance to BCG ( Bacillus Calmette–Guérin ) therapy. Pembrolizumab ( Keytruda...


Programmed cell death protein ligand-1 ( PD-L1 ) inhibitors are novel anti-cancer therapies but are associated with potentially therapy limiting...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Keytruda ( Pembrolizumab ) for the...


The European Commission ( EC ) has approved Opdivo ( Nivolumab ) for the treatment of locally advanced unresectable or...


Data from all three cohorts of the registrational, phase 2 KEYNOTE-059 trial investigating the use of Pembrolizumab ( Keytruda ),...